Tinostamustine

Verified

Overview

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

In preclinical studies, Tinostamustine has been shown to improve access to the DNA strands within cancer cells, damaging the cancer cells, DNA and preventing it from repairing itself.

SparkCures ID 225
Developed By Mundipharma EDO GmbH
Generic Name Tinostamustine
Additional Names EDO-S101
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Mundipharma EDO GmbH to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners